Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.73 |
| ▸ | KIT | P10721 | 1/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.73 |
| ▸ | CDK11B | P21127 | 1/20 | 0.73 |
| ▸ | FLT3 | P36888 | 1/20 | 0.73 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | BRAF | P15056 | 5/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12336691 | 0.92 | PDGFRB (0.62) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336258 | 0.92 | PDGFRB (0.62) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949289 | 0.92 | PDGFRB (0.61) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336421 | 0.92 | PDGFRB (0.61) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336269 | 0.91 | PDGFRB (0.61) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336250 | 0.91 | PDGFRB (0.61) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12348796 | 0.91 | PDGFRB (0.61) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12348785 | 0.91 | PDGFRB (0.60) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336268 | 0.90 | PDGFRB (0.60) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336756 | 0.90 | PDGFRB (0.59) | PDGFRBKITPDGFRACDK11BFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-10 | — | — | US | claimed |
| WO-2012021778-A2 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | claimed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20160237064-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9260417-B2 | Therapeutic methods and compositions involving allosteric kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140296268-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| WO-2011097594-A2 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | KINAGEN, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20060079526-A1 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237064-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | TIE1, PRKCH, PACSIN2 | PDGFRB 486/4885KIT 799/4885PDGFRA 644/4885 |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | PDGFRB 2469/4885KIT 1943/4885PDGFRA 2533/4885 |
| US-20060079526-A1 | Heterocyclic compounds and methods of use | AADAC, NISCH, PAICS | PDGFRB 2469/4885KIT 1943/4885PDGFRA 2533/4885 |
| US-20140296268-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | TIE1, PRKCH, PACSIN2 | PDGFRB 486/4885KIT 799/4885PDGFRA 644/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | PDGFRB 2469/4885KIT 1943/4885PDGFRA 2533/4885 |
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | BRAF, BUB1B, MKI67 | PDGFRB 1405/4885KIT 1806/4885PDGFRA 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.